{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:46:54Z","timestamp":1776919614932,"version":"3.51.2"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"am","delay-in-days":239,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA047924"],"award-info":[{"award-number":["R01DA047924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA035714"],"award-info":[{"award-number":["R01DA035714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmcl.2025.130345","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:25:37Z","timestamp":1753313137000},"page":"130345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and evaluation of novel substituted N-(2-phenylbutyl)-5,6,7,8-tetrahydro-quinazolin-4-amines as allosteric modulators of HIV-DAT-tat interaction"],"prefix":"10.1016","volume":"128","author":[{"given":"Theresa H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Moukha-Chafiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuklendu","family":"Karyakarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"Jimenez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne E.","family":"Augelli-Szafran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2025.130345_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAD.0000000000003379","article-title":"The global burden of cognitive impairment in people with HIV","volume":"37","author":"Keng","year":"2023","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130345_bb0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00005053-200102000-00002","article-title":"Evolution of depressive symptoms in human immunodeficiency virus-infected patients entering primary care","volume":"189","author":"Savetsky","year":"2001","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130345_bb0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11904-008-0025-1","article-title":"HIV and depression: 2008 review and update","volume":"5","author":"Rabkin","year":"2008","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130345_bb0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10461-008-9435-8","article-title":"Anxiety and depression symptoms as risk factors for non-adherence to antiretroviral therapy in Brazil","volume":"14","author":"Campos","year":"2010","journal-title":"AIDS Behav"},{"issue":"10","key":"10.1016\/j.bmcl.2025.130345_bb0025","first-page":"Wc01","article-title":"Prevalence of depression in people living with HIV\/AIDS undergoing ART and Factors associated with it","volume":"8","author":"Bhatia","year":"2014","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130345_bb0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1176\/jnp.10.3.320","article-title":"Apathy, depression, and cognitive performance in HIV-1 infection","volume":"10","author":"Castellon","year":"1998","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"10.1016\/j.bmcl.2025.130345_bb0035","article-title":"Prevalence and factors associated with common mental disorders in young people living with HIV in sub-Saharan Africa: a systematic review","volume":"24 Suppl 2 (Suppl 2)","author":"Too","year":"2021","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.bmcl.2025.130345_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/135502801300069737","article-title":"Acceleration of HIV dementia with methamphetamine and cocaine","volume":"7","author":"Nath","year":"2001","journal-title":"J NeuroVirol"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130345_bb0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.neubiorev.2008.01.004","article-title":"Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS","volume":"32","author":"Ferris","year":"2008","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130345_bb0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/187152612798994939","article-title":"Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein","volume":"12","author":"Mediouni","year":"2012","journal-title":"Infect Disord Drug Targets"},{"issue":"33","key":"10.1016\/j.bmcl.2025.130345_bb0055","doi-asserted-by":"crossref","first-page":"13588","DOI":"10.1073\/pnas.1308673110","article-title":"Induction of IL-17 and nonclassical T-cell activation by HIV-tat protein","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130345_bb0060","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.bbi.2011.05.006","article-title":"Intracerebroventricular administration of HIV-1 tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression","volume":"25","author":"Lawson","year":"2011","journal-title":"Brain Behav Immun"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130345_bb0065","first-page":"221","article-title":"Detection of HIV-1 tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy","volume":"6","author":"Del Valle","year":"2000","journal-title":"J Neuro-Oncol"},{"issue":"21","key":"10.1016\/j.bmcl.2025.130345_bb0070","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.1073\/pnas.97.21.11466","article-title":"Selective CXCR4 antagonism by tat: implications for in vivo expansion of coreceptor use by HIV-1","volume":"97","author":"Xiao","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130345_bb0075","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/syn.20949","article-title":"Recombinant human immunodeficiency virus-1 transactivator of transcription1\u201386 allosterically modulates dopamine transporter activity","volume":"65","author":"Zhu","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.bmcl.2025.130345_bb0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pharmthera.2017.10.007","article-title":"The role of human dopamine transporter in NeuroAIDS","volume":"183","author":"Zhu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2025.130345_bb0085","doi-asserted-by":"crossref","first-page":"39048","DOI":"10.1038\/srep39048","article-title":"Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 tat protein-inhibited dopamine transport","volume":"6","author":"Quizon","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130345_bb0090","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s11481-013-9464-6","article-title":"Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 tat-induced inhibition of dopamine transport and transporter conformational transitions","volume":"8","author":"Midde","year":"2013","journal-title":"J NeuroImmune Pharmacol"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130345_bb0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11481-015-9583-3","article-title":"Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 tat-induced inhibition of dopamine transport","volume":"10","author":"Midde","year":"2015","journal-title":"J NeuroImmune Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130345_bb0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/acschemneuro.5b00001","article-title":"Molecular mechanism of HIV-1 tat interacting with human dopamine transporter","volume":"6","author":"Yuan","year":"2015","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130345_bb0105","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11481-021-09984-5","article-title":"Mutations of human DopamineTransporter at Tyrosine88, aspartic Acid206, and Histidine547 influence basal and HIV-1 tat-inhibited dopamine transport","volume":"16","author":"Quizon","year":"2021","journal-title":"J NeuroImmune Pharmacol"},{"issue":"53","key":"10.1016\/j.bmcl.2025.130345_bb0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/syn.20048","article-title":"Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter","volume":"2004","author":"Nandi","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.bmcl.2025.130345_bb0115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/jpet.108.139675","article-title":"Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release","volume":"326","author":"Pariser","year":"2008","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.bmcl.2025.130345_bb0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/jpet.114.222299","article-title":"Studies of the biogenic amine transporters. Identification of novel allosteric dopamine transporter ligands with nanomolar potency","volume":"353","author":"Rothman","year":"2015","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.bmcl.2025.130345_bb0125","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/jpet.108.149088","article-title":"Studies of the biogenic amine transporters. 13. Identification of \"agonist\" and \"antagonist\" allosteric modulators of amphetamine-induced dopamine release","volume":"329","author":"Rothman","year":"2009","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.bmcl.2025.130345_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109239","article-title":"SRI-32743, a novel allosteric modulator, attenuates HIV-1 tat protein-induced inhibition of the dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 tat transgenic mice","volume":"220","author":"Zhu","year":"2022","journal-title":"Neuropharmacology"},{"issue":"14","key":"10.1016\/j.bmcl.2025.130345_bb0135","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.3390\/ijms25147881","article-title":"Effects of SRI-32743, a novel Quinazoline structure-based compound, on HIV-1 tat and cocaine interaction with norepinephrine transporter","volume":"25","author":"Jim\u00e9nez-Torres","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"8025","key":"10.1016\/j.bmcl.2025.130345_bb0140","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41586-024-07796-0","article-title":"Dopamine reuptake and inhibitory mechanisms in human dopamine transporter","volume":"632","author":"Li","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130345_bb0145","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1038\/s41598-017-03771-0","article-title":"Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 tat protein binding to human dopamine transporter","volume":"7","author":"Sun","year":"2017","journal-title":"Sci Rep"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:20:31Z","timestamp":1776918031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25002549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"alternative-id":["S0960894X25002549"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130345","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of novel substituted N-(2-phenylbutyl)-5,6,7,8-tetrahydro-quinazolin-4-amines as allosteric modulators of HIV-DAT-tat interaction","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130345"}}